Click here to get full coverage on Why Intra-Cellular Therapies (ITCI) Is Skyrocketing Now - Yahoo Finance

Why Intra-Cellular Therapies (ITCI) Is Skyrocketing Now  Yahoo Finance

Why Intra-Cellular Therapies (ITCI) Is Skyrocketing Now - Yahoo Finance

Click here to get full coverage on ITCI Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Intra-cellular Therapies, Inc. Is Fair to Shareholders - Business Wire

ITCI Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Intra-cellular Therapies, Inc. Is Fair to Shareholders  Business Wire

ITCI Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Intra-cellular Therapies, Inc. Is Fair to Shareholders - Business Wire

Click here to get full coverage on J&J to buy neurological drugmaker Intra-Cellular for $14.6 billion - CNBC

J&J to buy neurological drugmaker Intra-Cellular for $14.6 billion  CNBC

J&J to buy neurological drugmaker Intra-Cellular for $14.6 billion - CNBC

Click here to get full coverage on Johnson & Johnson Acquires Intra-Cellular Therapies: What You Need to Know (ITCI Merger) - tradingcalendar.com

Johnson & Johnson Acquires Intra-Cellular Therapies: What You Need to Know (ITCI Merger)  tradingcalendar.com

Johnson & Johnson Acquires Intra-Cellular Therapies: What You Need to Know (ITCI Merger) - tradingcalendar.com

Click here to get full coverage on Johnson & Johnson Strengthens Neuroscience Leadership with Acquisition of Intra-Cellular Therapies, Inc. - GlobeNewswire

Johnson & Johnson Strengthens Neuroscience Leadership with Acquisition of Intra-Cellular Therapies, Inc.  GlobeNewswire

Johnson & Johnson Strengthens Neuroscience Leadership with Acquisition of Intra-Cellular Therapies, Inc. - GlobeNewswire

Click here to get full coverage on Johnson & Johnson (JNJ) Closes Intra-Cellular Therapies, Inc. (ITCI) Acquisition - StreetInsider

Johnson & Johnson (JNJ) Closes Intra-Cellular Therapies, Inc. (ITCI) Acquisition  StreetInsider

Johnson & Johnson (JNJ) Closes Intra-Cellular Therapies, Inc. (ITCI) Acquisition - StreetInsider

Click here to get full coverage on Johnson & Johnson: No More Tears, Just Gains In Intra-Cellular Acquisition - Seeking Alpha

Johnson & Johnson: No More Tears, Just Gains In Intra-Cellular Acquisition  Seeking Alpha

Johnson & Johnson: No More Tears, Just Gains In Intra-Cellular Acquisition - Seeking Alpha

Click here to get full coverage on Intra-Cellular Therapies Stock Pops as Johnson & Johnson Buys Firm for $14.6B - Investopedia

Intra-Cellular Therapies Stock Pops as Johnson & Johnson Buys Firm for $14.6B  Investopedia

Intra-Cellular Therapies Stock Pops as Johnson & Johnson Buys Firm for $14.6B - Investopedia

Click here to get full coverage on Intra-Cellular Therapies acquired by Johnson & Johnson for $14.6 billion - Investing.com

Intra-Cellular Therapies acquired by Johnson & Johnson for $14.6 billion  Investing.com

Intra-Cellular Therapies acquired by Johnson & Johnson for $14.6 billion - Investing.com

Click here to get full coverage on Simultaneous pharmacometric control optimization for advanced integrated multi-drug target infusions - ScienceDirect.com

Simultaneous pharmacometric control optimization for advanced integrated multi-drug target infusions  ScienceDirect.com

Simultaneous pharmacometric control optimization for advanced integrated multi-drug target infusions - ScienceDirect.com

Click here to get full coverage on J&J doubles down on neurological drugs with $14.6 billion Intra-Cellular deal - Reuters

J&J doubles down on neurological drugs with $14.6 billion Intra-Cellular deal  Reuters

J&J doubles down on neurological drugs with $14.6 billion Intra-Cellular deal - Reuters

Click here to get full coverage on J&J Announces A Splashy $14.6 Billion Deal, While Lilly Tacks On A Cancer Drug - Investor's Business Daily

J&J Announces A Splashy $14.6 Billion Deal, While Lilly Tacks On A Cancer Drug  Investor's Business Daily

J&J Announces A Splashy $14.6 Billion Deal, While Lilly Tacks On A Cancer Drug - Investor's Business Daily

Click here to get full coverage on ITCI Stock Surges 34% as J&J Reveals $14.6 Billion Acquisition Plan - Yahoo Finance

ITCI Stock Surges 34% as J&J Reveals $14.6 Billion Acquisition Plan  Yahoo Finance

ITCI Stock Surges 34% as J&J Reveals $14.6 Billion Acquisition Plan - Yahoo Finance

Click here to get full coverage on Intra-Cellular Therapies: Parkinson's Disease Drug Expansion Could Be The Next Huge Move - Seeking Alpha

Intra-Cellular Therapies: Parkinson's Disease Drug Expansion Could Be The Next Huge Move  Seeking Alpha

Intra-Cellular Therapies: Parkinson's Disease Drug Expansion Could Be The Next Huge Move - Seeking Alpha

Click here to get full coverage on Intra-Cellular Therapies (ITCI): Among the Best Biotech Stocks to Buy According to Billionaires - Yahoo Finance

Intra-Cellular Therapies (ITCI): Among the Best Biotech Stocks to Buy According to Billionaires  Yahoo Finance

Intra-Cellular Therapies (ITCI): Among the Best Biotech Stocks to Buy According to Billionaires - Yahoo Finance

Click here to get full coverage on Why Intra-Cellular Therapies, Inc. (ITCI) Is Skyrocketing Now - Yahoo Finance

Why Intra-Cellular Therapies, Inc. (ITCI) Is Skyrocketing Now  Yahoo Finance

Why Intra-Cellular Therapies, Inc. (ITCI) Is Skyrocketing Now - Yahoo Finance

Click here to get full coverage on ITCI Q4 Loss Wider Than Expected, Revenues Top on Higher Caplyta Sales - Yahoo Finance

ITCI Q4 Loss Wider Than Expected, Revenues Top on Higher Caplyta Sales  Yahoo Finance

ITCI Q4 Loss Wider Than Expected, Revenues Top on Higher Caplyta Sales - Yahoo Finance

Click here to get full coverage on Intra-Cellular Therapies (ITCI) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance

Intra-Cellular Therapies (ITCI) Reports Q4 Loss, Tops Revenue Estimates  Yahoo Finance

Intra-Cellular Therapies (ITCI) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance

Click here to get full coverage on Intra-Cellular Therapies, Inc. (ITCI): Among the Best Psychedelic Stocks to Buy in 2025 - Yahoo Finance

Intra-Cellular Therapies, Inc. (ITCI): Among the Best Psychedelic Stocks to Buy in 2025  Yahoo Finance

Intra-Cellular Therapies, Inc. (ITCI): Among the Best Psychedelic Stocks to Buy in 2025 - Yahoo Finance

Click here to get full coverage on ITCI Stock Rises 15% on Settling Caplyta Patent Litigation With Sandoz - Yahoo Finance

ITCI Stock Rises 15% on Settling Caplyta Patent Litigation With Sandoz  Yahoo Finance

ITCI Stock Rises 15% on Settling Caplyta Patent Litigation With Sandoz - Yahoo Finance

Click here to get full coverage on Intra-Cellular Therapies Soars 32% With Johnson & Johnson's $14.6B Acquisition - Yahoo Finance

Intra-Cellular Therapies Soars 32% With Johnson & Johnson's $14.6B Acquisition  Yahoo Finance

Intra-Cellular Therapies Soars 32% With Johnson & Johnson's $14.6B Acquisition - Yahoo Finance

Click here to get full coverage on Intra-Cellular Therapies CEO to Present at J.P. Morgan Healthcare Conference 2025 - Stock Titan

Intra-Cellular Therapies CEO to Present at J.P. Morgan Healthcare Conference 2025  Stock Titan

Intra-Cellular Therapies CEO to Present at J.P. Morgan Healthcare Conference 2025 - Stock Titan

Click here to get full coverage on Intra-Cellular Therapies Completes Merger with Johnson & Johnson - TipRanks

Intra-Cellular Therapies Completes Merger with Johnson & Johnson  TipRanks

Intra-Cellular Therapies Completes Merger with Johnson & Johnson - TipRanks

Click here to get full coverage on Intra-Cellular Therapies progresses in Johnson & Johnson merger - Investing.com

Intra-Cellular Therapies progresses in Johnson & Johnson merger  Investing.com

Intra-Cellular Therapies progresses in Johnson & Johnson merger - Investing.com

Click here to get full coverage on J&J CEO broke a stalemate and facilitated the $14.6B Intra-Cellular buyout in a whirlwind month: filing - Fierce Pharma

J&J CEO broke a stalemate and facilitated the $14.6B Intra-Cellular buyout in a whirlwind month: filing  Fierce Pharma

J&J CEO broke a stalemate and facilitated the $14.6B Intra-Cellular buyout in a whirlwind month: filing - Fierce Pharma

Click here to get full coverage on Intra-Cellular Therapies Shareholders Approve Johnson & Johnson Merger - Investing.com

Intra-Cellular Therapies Shareholders Approve Johnson & Johnson Merger  Investing.com

Intra-Cellular Therapies Shareholders Approve Johnson & Johnson Merger - Investing.com

Click here to get full coverage on What Johnson & Johnson Is Getting With The Acquisition Of Intra-Cellular Therapies (ITCI) - Seeking Alpha

What Johnson & Johnson Is Getting With The Acquisition Of Intra-Cellular Therapies (ITCI)  Seeking Alpha

What Johnson & Johnson Is Getting With The Acquisition Of Intra-Cellular Therapies (ITCI) - Seeking Alpha

Click here to get full coverage on JNJ, GSK, LLY Announce M&A Deals at JP Morgan Conference - Yahoo Finance

JNJ, GSK, LLY Announce M&A Deals at JP Morgan Conference  Yahoo Finance

JNJ, GSK, LLY Announce M&A Deals at JP Morgan Conference - Yahoo Finance

Click here to get full coverage on Intra-Cellular Therapies Secures CAPLYTA Patent Protection Until 2040 in Sandoz Settlement - Stock Titan

Intra-Cellular Therapies Secures CAPLYTA Patent Protection Until 2040 in Sandoz Settlement  Stock Titan

Intra-Cellular Therapies Secures CAPLYTA Patent Protection Until 2040 in Sandoz Settlement - Stock Titan

Click here to get full coverage on J&J Bolsters Its Prospects in Brain Health With $14B Buyout of Intra-Cellular Therapies - MedCity News

J&J Bolsters Its Prospects in Brain Health With $14B Buyout of Intra-Cellular Therapies  MedCity News

J&J Bolsters Its Prospects in Brain Health With $14B Buyout of Intra-Cellular Therapies - MedCity News

Click here to get full coverage on J&J punts $14.6 billion on buy of Intra-Cellular Therapies - The Pharma Letter

J&J punts $14.6 billion on buy of Intra-Cellular Therapies  The Pharma Letter

J&J punts $14.6 billion on buy of Intra-Cellular Therapies - The Pharma Letter

Click here to get full coverage on J&J explores bid for Intra-Cellular Therapies, Bloomberg News reports - Reuters

J&J explores bid for Intra-Cellular Therapies, Bloomberg News reports  Reuters

J&J explores bid for Intra-Cellular Therapies, Bloomberg News reports - Reuters

Click here to get full coverage on Johnson & Johnson to Expand Neuroscience Portfolio with US$14.6 Billion Acquisition - Investing News Network

Johnson & Johnson to Expand Neuroscience Portfolio with US$14.6 Billion Acquisition  Investing News Network

Johnson & Johnson to Expand Neuroscience Portfolio with US$14.6 Billion Acquisition - Investing News Network

Click here to get full coverage on Intra-Cellular Therapies Stock Up 34% on J&J's $14.6B Buyout Offer - Zacks Investment Research

Intra-Cellular Therapies Stock Up 34% on J&J's $14.6B Buyout Offer  Zacks Investment Research

Intra-Cellular Therapies Stock Up 34% on J&J's $14.6B Buyout Offer - Zacks Investment Research

Click here to get full coverage on J&J to Acquire Intra-Cellular for About $14.6 Billion - Bloomberg.com

J&J to Acquire Intra-Cellular for About $14.6 Billion  Bloomberg.com

J&J to Acquire Intra-Cellular for About $14.6 Billion - Bloomberg.com

Click here to get full coverage on Intra-Cellular Therapies: Acquisition Anticipation? - timothysykes.com

Intra-Cellular Therapies: Acquisition Anticipation?  timothysykes.com

Intra-Cellular Therapies: Acquisition Anticipation? - timothysykes.com

Click here to get full coverage on Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2024 Financial Results - GlobeNewswire

Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2024 Financial Results  GlobeNewswire

Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2024 Financial Results - GlobeNewswire

Click here to get full coverage on Intra-Cellular Therapies Settles CAPLYTA® (lumateperone) Patent Litigation with Sandoz - The Globe and Mail

Intra-Cellular Therapies Settles CAPLYTA® (lumateperone) Patent Litigation with Sandoz  The Globe and Mail

Intra-Cellular Therapies Settles CAPLYTA® (lumateperone) Patent Litigation with Sandoz - The Globe and Mail

Click here to get full coverage on Intra-Cellular Therapies: Analyzing Market Trends and Predictions - timothysykes.com

Intra-Cellular Therapies: Analyzing Market Trends and Predictions  timothysykes.com

Intra-Cellular Therapies: Analyzing Market Trends and Predictions - timothysykes.com

Click here to get full coverage on Intra-Cellular Therapies to Present at the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewswire

Intra-Cellular Therapies to Present at the 43rd Annual J.P. Morgan Healthcare Conference  GlobeNewswire

Intra-Cellular Therapies to Present at the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewswire

Click here to get full coverage on Johnson & Johnson Eyes Intra-Cellular Therapies Acquisition: An Unexpected Twist or Strategic Genius? - timothysykes.com

Johnson & Johnson Eyes Intra-Cellular Therapies Acquisition: An Unexpected Twist or Strategic Genius?  timothysykes.com

Johnson & Johnson Eyes Intra-Cellular Therapies Acquisition: An Unexpected Twist or Strategic Genius? - timothysykes.com

Click here to get full coverage on Intra-Cellular Therapies Submits Supplemental New Drug - GlobeNewswire

Intra-Cellular Therapies Submits Supplemental New Drug  GlobeNewswire

Intra-Cellular Therapies Submits Supplemental New Drug - GlobeNewswire

Click here to get full coverage on Intra-Cellular Therapies and Sandoz Reach Settlement in CAPLYTA Patent Litigation - Quiver Quantitative

Intra-Cellular Therapies and Sandoz Reach Settlement in CAPLYTA Patent Litigation  Quiver Quantitative

Intra-Cellular Therapies and Sandoz Reach Settlement in CAPLYTA Patent Litigation - Quiver Quantitative

Click here to get full coverage on Johnson & Johnson exploring takeover of Intra-Cellular - Bloomberg - MSN

Johnson & Johnson exploring takeover of Intra-Cellular - Bloomberg  MSN

Johnson & Johnson exploring takeover of Intra-Cellular - Bloomberg - MSN

Click here to get full coverage on Johnson & Johnson acquires Intra-Cellular Therapies - Investing.com

Johnson & Johnson acquires Intra-Cellular Therapies  Investing.com

Johnson & Johnson acquires Intra-Cellular Therapies - Investing.com

Click here to get full coverage on International Tax Competitiveness Index 2024 - Tax Foundation

International Tax Competitiveness Index 2024  Tax Foundation

International Tax Competitiveness Index 2024 - Tax Foundation

Click here to get full coverage on Peaking Back In On Intra-Cellular Therapies (NASDAQ:ITCI) - Seeking Alpha

Peaking Back In On Intra-Cellular Therapies (NASDAQ:ITCI)  Seeking Alpha

Peaking Back In On Intra-Cellular Therapies (NASDAQ:ITCI) - Seeking Alpha

Click here to get full coverage on JPMorgan Chase & Co's Strategic Acquisition of Shares in Intra-Cellular Therapies Inc - Yahoo Finance

JPMorgan Chase & Co's Strategic Acquisition of Shares in Intra-Cellular Therapies Inc  Yahoo Finance

JPMorgan Chase & Co's Strategic Acquisition of Shares in Intra-Cellular Therapies Inc - Yahoo Finance

Click here to get full coverage on Intra-Cellular Therapies Is On Fire (NASDAQ:ITCI) - Seeking Alpha

Intra-Cellular Therapies Is On Fire (NASDAQ:ITCI)  Seeking Alpha

Intra-Cellular Therapies Is On Fire (NASDAQ:ITCI) - Seeking Alpha

Click here to get full coverage on Intra-Cellular Therapies Announces Presentations at the 2024 Psych Congress and NEI Congress - Yahoo Finance

Intra-Cellular Therapies Announces Presentations at the 2024 Psych Congress and NEI Congress  Yahoo Finance

Intra-Cellular Therapies Announces Presentations at the 2024 Psych Congress and NEI Congress - Yahoo Finance

Click here to get full coverage on Intra-Cellular Therapies to Host Second Quarter 2024 Financial Results Conference Call and Webcast - Stock Titan

Intra-Cellular Therapies to Host Second Quarter 2024 Financial Results Conference Call and Webcast  Stock Titan

Intra-Cellular Therapies to Host Second Quarter 2024 Financial Results Conference Call and Webcast - Stock Titan

Click here to get full coverage on ITCI Stock on the Rise: Analyzing the Latest Strategy and Market Response - timothysykes.com

ITCI Stock on the Rise: Analyzing the Latest Strategy and Market Response  timothysykes.com

ITCI Stock on the Rise: Analyzing the Latest Strategy and Market Response - timothysykes.com

Click here to get full coverage on Drugmaker Intra-Cellular (ITCI) Soars as Depression Trial Succeeds - Bloomberg.com

Drugmaker Intra-Cellular (ITCI) Soars as Depression Trial Succeeds  Bloomberg.com

Drugmaker Intra-Cellular (ITCI) Soars as Depression Trial Succeeds - Bloomberg.com

Click here to get full coverage on J&J to acquire drugmaker Intra-Cellular Therapies for $14.6 billion - Business Standard

J&J to acquire drugmaker Intra-Cellular Therapies for $14.6 billion  Business Standard

J&J to acquire drugmaker Intra-Cellular Therapies for $14.6 billion - Business Standard

Click here to get full coverage on Intra-Cellular Therapies Presents Data from the CAPLYTA - GlobeNewswire

Intra-Cellular Therapies Presents Data from the CAPLYTA  GlobeNewswire

Intra-Cellular Therapies Presents Data from the CAPLYTA - GlobeNewswire

Click here to get full coverage on The Right Play On Intra-Cellular Therapies (NASDAQ:ITCI) - Seeking Alpha

The Right Play On Intra-Cellular Therapies (NASDAQ:ITCI)  Seeking Alpha

The Right Play On Intra-Cellular Therapies (NASDAQ:ITCI) - Seeking Alpha

Click here to get full coverage on Intra-Cellular (ITCI) Q4 Earnings & Sales Top, Caplyta Shines - Nasdaq

Intra-Cellular (ITCI) Q4 Earnings & Sales Top, Caplyta Shines  Nasdaq

Intra-Cellular (ITCI) Q4 Earnings & Sales Top, Caplyta Shines - Nasdaq

Click here to get full coverage on Intra-Cellular Therapies Announces Closing of $575 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares - Yahoo Finance

Intra-Cellular Therapies Announces Closing of $575 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares  Yahoo Finance

Intra-Cellular Therapies Announces Closing of $575 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares - Yahoo Finance

Click here to get full coverage on Intra-Cellular's Caplyta Is Likely A Blockbuster For Bipolar Depression (NASDAQ:ITCI) - Seeking Alpha

Intra-Cellular's Caplyta Is Likely A Blockbuster For Bipolar Depression (NASDAQ:ITCI)  Seeking Alpha

Intra-Cellular's Caplyta Is Likely A Blockbuster For Bipolar Depression (NASDAQ:ITCI) - Seeking Alpha

Click here to get full coverage on Piper Sandler sees $4B peak sales for Caplyta, driving Intra-Cellular stock upgrade - Investing.com

Piper Sandler sees $4B peak sales for Caplyta, driving Intra-Cellular stock upgrade  Investing.com

Piper Sandler sees $4B peak sales for Caplyta, driving Intra-Cellular stock upgrade - Investing.com

Click here to get full coverage on Why Earnings Season Could Be Great for Intra-Cellular Therapies (ITCI) - Yahoo Finance

Why Earnings Season Could Be Great for Intra-Cellular Therapies (ITCI)  Yahoo Finance

Why Earnings Season Could Be Great for Intra-Cellular Therapies (ITCI) - Yahoo Finance

Click here to get full coverage on Intra-Cellular Therapies Appoints Sanjeev Narula as Chief Financial Officer - citybiz

Intra-Cellular Therapies Appoints Sanjeev Narula as Chief Financial Officer  citybiz

Intra-Cellular Therapies Appoints Sanjeev Narula as Chief Financial Officer - citybiz

Click here to get full coverage on Learn to Evaluate (ITCI) using the Charts - news.stocktradersdaily.com

Learn to Evaluate (ITCI) using the Charts  news.stocktradersdaily.com

Learn to Evaluate (ITCI) using the Charts - news.stocktradersdaily.com

Click here to get full coverage on Intra-Cellular's Caplyta Sales Boost Revenues, Dependence a Woe - Yahoo Finance

Intra-Cellular's Caplyta Sales Boost Revenues, Dependence a Woe  Yahoo Finance

Intra-Cellular's Caplyta Sales Boost Revenues, Dependence a Woe - Yahoo Finance

Click here to get full coverage on Sharon Mates - Forbes

Sharon Mates - Forbes

Click here to get full coverage on Intra-Cellular Therapies Announces Positive Phase 3 Topline - GlobeNewswire

Intra-Cellular Therapies Announces Positive Phase 3 Topline  GlobeNewswire

Intra-Cellular Therapies Announces Positive Phase 3 Topline - GlobeNewswire

Click here to get full coverage on Intra-Cellular Therapies to Present at the Goldman Sachs 44th Annual Global Healthcare Conference - Stock Titan

Intra-Cellular Therapies to Present at the Goldman Sachs 44th Annual Global Healthcare Conference  Stock Titan

Intra-Cellular Therapies to Present at the Goldman Sachs 44th Annual Global Healthcare Conference - Stock Titan

Click here to get full coverage on Intra-Cellular Therapies Reports Third Quarter 2024 - GlobeNewswire

Intra-Cellular Therapies Reports Third Quarter 2024  GlobeNewswire

ITCI

Price Chart

Key Statistics

Technicals

About ITCI

Latest News

Why Intra-Cellular Therapies (ITCI) Is Skyrocketing Now - Yahoo Finance

ITCI Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Intra-cellular Therapies, Inc. Is Fair to Shareholders - Business Wire

J&J to buy neurological drugmaker Intra-Cellular for $14.6 billion - CNBC

Advanced Charts

Top Gainers

Top Losers